New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme

• Published in: Journal of medicinal chemistry Vol. 64; no. 9; pp. 6300 - 6309
• Main Authors: Hay, Bruce A, Godugu, Kavitha, Darwish, Noureldien H. E, Fujioka, Kazutoshi, Sudha, Thangirala, Karakus, Ozlem Ozen, Mousa, Shaker A
• Format: Journal Article
• Language: English
• Published: American Chemical Society 13.05.2021
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.1c00350

We have previously reported that the αvβ3 inhibitor P-bi-TAT, a bifunctional version of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) conjugated to polyethylene glycol (PEG) MW 4000, has excellent efficacy in a glioblastoma multiforme (GBM) mouse model. However, bioanalysis problems due to PEG polydispersity and large-scale synthesis issues led to a search for new molecules, culminating in the discovery of fb-PMT, a conjugate of tetrac and monodisperse PEG36, with a lipophilic 4-fluorobenzyl group at the opposite end of the PEG chain. fb-PMT reduces GBM tumor growth and viability by up to 98%, is suitable for large-scale synthesis, and is amenable to bioanalysis using mass spectrometry-based detection. We also showed that changes in lipophilicity at the opposite end of the PEG chain from the active tetrac component affected the proton NMR chemical shift of the tetrac moiety in D20 and brain levels of the compound after subcutaneous dosing.